In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Balchem (BCPC – Research Report), with a price target of $190.00.
Ram Selvaraju’s rating is based on the belief that Balchem’s long-term growth prospects remain strong despite a modest miss in recent financial targets. The company reported slightly lower-than-expected revenue and earnings for the fourth quarter and full year of 2024, but Selvaraju remains optimistic about future performance, particularly in the Human Nutrition and Health (HNH) segment, which is expected to drive revenue growth in the coming quarters.
Balchem’s new product launches, including K2Vital Delta Fermented and VitaCholine Pro-Flo, are positioned to enhance market demand, especially with the significant partnership with FC Bayern Women’s soccer team. This partnership is seen as a strategic move to strengthen Balchem’s brand presence and bridge B2B and B2C markets. Despite slight adjustments in revenue and earnings forecasts, Selvaraju maintains a Buy rating, with a 12-month price target of $190, reflecting confidence in Balchem’s strategic initiatives and product innovations to sustain growth.
According to TipRanks, Selvaraju is a 4-star analyst with an average return of 5.1% and a 39.36% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Vanda, Axsome Therapeutics, and Anavex Life Sciences.